	US 12,465,624 B2
	Cancer immunotherapy using virus particles and immune checkpoint therapy
Nicole F. Steinmetz, San Diego, CA (US); and Chao Wang, Cleveland, OH (US)
Assigned to CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Filed by CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Filed on Jul. 7, 2021, as Appl. No. 17/369,405.
Application 17/369,405 is a continuation in part of application No. 16/612,214, granted, now 11,617,787, previously published as PCT/US2018/031661, filed on May 8, 2018.
Claims priority of provisional application 63/049,434, filed on Jul. 8, 2020.
Prior Publication US 2021/0361728 A1, Nov. 25, 2021
Int. Cl. A61K 39/12 (2006.01); A61K 35/768 (2015.01); A61K 39/125 (2006.01); A61K 39/295 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)

CPC A61K 35/768 (2013.01) [A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C12N 7/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01)]

16 Claims

1. A method of treating cancer in a subject, the method comprising administering in situ to the cancer of the subject a therapeutically effective amount of a cowpea mosaic virus or a cowpea mosaic virus-like particle in combination with administering an immune checkpoint therapy to the subject, wherein the cowpea mosaic virus and cowpea mosaic virus-like particles are not used as a vehicle for drug or antigen delivery.